{"id":"W3134647918","doi":"10.1200/jco.2021.39.6_suppl.429","title":"An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Durvalumab; Clinical endpoint; Discontinuation; Internal medicine; Adverse effect; Urology; Cisplatin; Tolerability; Response Evaluation Criteria in Solid Tumors; Oncology; Chemotherapy; Phases of clinical research; Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004895505,0.001530352,0.00198545,0.0003483114,0.0003729838,0.00101121,0.001055337,0.001275129,0.00453672],"category_scores_gemma":[0.00217979,0.0006496103,0.002268453,0.0005103433,0.0006912187,0.0008703202,0.0005575805,0.002394404,0.001343219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008690229,"about_ca_system_score_gemma":0.00172008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007599936,"about_ca_topic_score_gemma":0.001780088,"domain_scores_codex":[0.9986533,0.0008750234,0.00004833179,0.0001681021,0.0001029491,0.0001522915],"domain_scores_gemma":[0.9978858,0.0004322897,0.0005090505,0.0002296848,0.0001850725,0.0007581258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9059044,0.02089014,0.01575947,0.000817348,0.003953206,0.0001222216,0.0001612111,0.001817421,0.01393992,0.0002095465,0.005494202,0.03093096],"study_design_scores_gemma":[0.7070597,0.2424492,0.04103314,0.00005146544,0.001888043,0.0002110459,0.00006076662,0.001520227,0.001324527,0.0002801972,0.004079106,0.00004249523],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833828,0.002219925,0.001024825,0.0004730326,0.00009764755,0.005055529,0.005601937,0.00009980534,0.00204449],"genre_scores_gemma":[0.9757286,0.001185984,0.003278993,0.001146634,0.000163214,0.005448374,0.01018131,0.00005756018,0.002809394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004895505,"threshold_uncertainty_score":0.02589023,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1968864083643116,"score_gpt":0.5069534400515107,"score_spread":0.3100670316871991,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}